No spam - just the good stuff

Subscribe to our newsletter
Hidden
  • News
  • Investor Portal
  • Lifestyle
  • Videos

News

  • Home
  • Biotech
  • Investment
  • Diagnostics
  • Agetech
  • Supplements
  • Innovation
  • AI/Digital
  • Economy

InvestmentInvestor Portal

  • Investment portal
  • Investment portal login
  • Register as an investor
  • Raise finance

Lifestyle

  • Home
  • Supplements
  • Self-testing
  • Exercise
  • Nutrition
  • Tech
  • Mental wellness
  • Product reviews

More

  • Contact
  • Features

News

  • Home
  • Biotech
  • Investment
  • Diagnostics
  • Agetech
  • Supplements
  • Innovation
  • AI/Digital
  • Economy
Posted on August 4, 2023August 4, 2023

Inflammaging discovery could slow aging and prevent age-related diseases

Understanding – and increasing – calcium signaling could lead to new therapeutic strategies for age-associated inflammation. Researchers have discovered a …

Continue reading “Inflammaging discovery could slow aging and prevent age-related diseases”

Posted on May 18, 2023May 18, 2023

Going to bat against inflammaging

Protein found in bats could tackle inflammation – and aging. In the quest to unlock the secrets of aging, scientists …

Continue reading “Going to bat against inflammaging”

Posted on December 11, 2020May 11, 2022

NAD boosting to reverse senescence and inflammaging

Senescent cells promote NAD tissue decline during aging through CD38 enzymes which can now become a novel therapeutic target. Nicotinamide …

Continue reading “NAD boosting to reverse senescence and inflammaging”

Posted on December 8, 2020May 11, 2022

Targeting inflammaging through glycomics

Avenna claims the first reliable, quantitative biomarkers for subclinical systemic chronic inflammation. Using the science of glycomics, British start-up Avenna …

Continue reading “Targeting inflammaging through glycomics”

Posted on November 25, 2020May 11, 2022

Targeting inflammaging: the hidden “inflammapath” inside us

Keystone Bio seeks funding as it gears up for clinical trials of therapeutic targeting the “keystone pathogen” of chronic inflammaging. …

Continue reading “Targeting inflammaging: the hidden “inflammapath” inside us”

Posted on November 6, 2020May 23, 2022

Inflammaging – could ibuprofen be the answer?

Neurodegenerative disease is associated with age-related chronic, low grade inflammation, but studies suggest that this could be reversed with over …

Continue reading “Inflammaging – could ibuprofen be the answer?”

Posted on September 21, 2020May 11, 2022

Inflammaging biotech acquired by Roche for €380m

One of the largest deals in Irish biotech history sees Roche gain rights to full Inflazome portfolio. The Swiss company …

Continue reading “Inflammaging biotech acquired by Roche for €380m”

Posted on May 19, 2020May 10, 2022

Metformin boost for inflammaging research

Researchers use metformin to repair broken cell machinery and drastically lower dangerous inflammation. Inflammaging is one of the latest Longevity …

Continue reading “Metformin boost for inflammaging research”

Posted on June 16, 2023June 16, 2023

HCW Biologics lands US patent with senotherapeutic potential

Clinical-stage immunotherapy company HCW Biologics (NASDAQ: HCWB) was granted a new US patent which contains methods of use claims directed …

Continue reading “HCW Biologics lands US patent with senotherapeutic potential”

Posts navigation

Page 1 Page 2 … Page 7 Next page

Find us here ...

Subscribe to our newsletter

Hidden

News

  • Home
  • Biotech
  • Investment
  • Diagnostics
  • Agetech
  • Supplements
  • Innovation
  • AI/Digital
  • Economy

Investment

  • Investment portal
  • Investment portal login
  • Register as an investor
  • Raise finance

Lifestyle

  • Home
  • Supplements
  • Self-testing
  • Exercise
  • Nutrition
  • Tech
  • Mental wellness
  • Product reviews

More

  • Contact
  • Features
  • Editorial Policy
  • Privacy Policy
  • Cookie Policy
  • Conditions of Business
  • Terms and Conditions
  • Copyright Policy
© Copyright 2023 FIRST LONGEVITY Limited. All rights reserved. FIRST LONGEVITY
The information included in this website is for informational purposes only: its purpose is to promote a broad consumer understanding a knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.

DISCLAIMER FOR U.S. BASED INVESTORS
The Agent of First Longevity Limited in the United States is Marco Polo Securities Inc, a non-affiliated broker-dealer registered with the US Securities and Exchange Commission. The activities of First Longevity Limited in the United States will be affected only to the extent permitted by Rule 15a-6 under the US Securities Exchange Act of 1934 and in accordance with the Services Agreement entered into between First Longevity Limited and Marco Polo Securities Inc with respect thereto. Contact at Marco Polo Securities is clientservices@mpsecurities.com; 1-347-745-6448.